Akebia Therapeutics, Inc. - Common Stock (AKBA)

Akebia Therapeutics (NASDAQ:AKBA) outlined its commercial priorities for Vafseo, the expected evolution of reimbursement after the TDAPA period and several renal-disease pipeline programs during a fireside chat at the Jefferies 2026 Global Healthcare Conference. Erik, Akebia’s chief financial offic

Akebia (AKBA) Q1 2026 Earnings Transcript

Akebia (AKBA) Q4 2025 Earnings Call Transcript

The company said on Thursday that it now expects its mid-stage trial of AKB-097 in rare kidney diseases to start in the second half of 2026, with initial data expected in 2027.

The company said that the sale extends its cash runway into the second half of 2027.

Akebia shares decline after the company ends plans for its VALOR trial, citing FDA feedback and high costs tied to expanding Vafseo's label.

As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.